Key facts
- It has raised $1.5M; the latest was Early Stage VC in Apr 2025.
- Notable investors include Frees Fund, Triwise Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Mitouke
- ·The full record, as it builds
Funding rounds
No funding rounds for Mitouke are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mitouke
Provider and developer of cellular therapy drugs designed for pet industry. The company focuses on common illnesses for elderly pets, enabling pet owners with treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Mitouke doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mitouke shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mitouke in its N-PORT filings yet. We sweep new filings monthly.